Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Ryan, Caitriona; Guenther, Lyn; Foley, Peter; Weisman, Jamie; Burge, Russel; Gallo, Gaia; See, Kyoungah; McKean-Matthews, Missy; Bertram, Clinton C.; Merola, Joseph F.

doi:10.1111/jdv.17836

Cited by 3 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, we cannot determine whether the intensity of the SD reported by patients is related to the severity of their dermatological condition nor can we determine whether the treatments received by patients, and more specifically biological therapies, have led to an improvement as demonstrated in previous studies. 7 , 8 , 9 , 10 , 11 , 12 It would therefore be interesting to evaluate whether the improvement of psoriasis sexual disorders following treatment could also improve the psychological and relational consequences, in association with the use of patient guides and multidisciplinary management with sexologists and psychologists.…”

Section: Discussionmentioning

confidence: 99%

“…Psoriasis through its physical symptoms and psychological consequences can thus be responsible for SD 6 . Recent trials have demonstrated that biological therapies improve psoriasis patients' sexual function 7–12 . However, the tools most frequently used in studies to assess sexual dysfunction in psoriasis such as the International Index of Erectile Function‐5 (IIEF), and the Female Sexual Function Index (FSFI) do not allow a global and systemic assessment of the impact of the disease on patients' sexuality of both gender and focus mainly on genital function 6 .…”

Section: Introductionmentioning

confidence: 99%

“… 6 Recent trials have demonstrated that biological therapies improve psoriasis patients' sexual function. 7 , 8 , 9 , 10 , 11 , 12 However, the tools most frequently used in studies to assess sexual dysfunction in psoriasis such as the International Index of Erectile Function‐5 (IIEF), and the Female Sexual Function Index (FSFI) do not allow a global and systemic assessment of the impact of the disease on patients' sexuality of both gender and focus mainly on genital function. 6 Yet some studies have demonstrated that loss of self‐confidence related to the degradation of body image or the difficulty to reveal their intimacy in front of a sexual partner might actually be an important part of SD in psoriasis patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Psoriasis and sexuality: Patients express their feelings

Salle

Halioua

Fur³

et al. 2022

Skin Health and Disease

View full text Add to dashboard Cite

Background In France, psoriasis is a chronic inflammatory skin disease. For several years now, particular attention has been given to the quality of life (Qol) of psoriasis patients. Sexual dysfunction (SD) defined as not wanting or enjoying sexual experience is an important component of Qol. Psoriasis through its physical symptoms and psychological consequences can thus be responsible for SD. Method The survey participants were recruited through the national psoriasis dermatitis patient association. Result 41% (577) patients reported having SD related to their psoriasis. Women reported significantly more SD than men (387 [44.7%] vs. 190 [35%], p < 0.001). For 396 (28.1%) patients SD due to their psoriasis manifested as a reduction in the frequency of sexual activity, for 207 (14.7%) as change in their sexual practice, and for 284 (27.4%) as an absence of sexual activity without significant difference between women and men. The main consequence of sexual difficulties for patients was loss of self‐confidence in 627 (44.5%) cases, guilt in 209 (14.8%) cases, couple life impairment in 214 (15.2%) cases, isolation in 260 (18.5%) cases and frustration. Discussion In this study investigating SD related to psoriasis, we found that the disease impact sexual relations of 41% of patients of both gender. The main causes of SD were both physical alone and psychological alone, in the same proportions. The physical symptoms of psoriasis are therefore not the only ones responsible for the sexual discomfort reported from patients in their sexual relations. This may be due to a discomfort of the patient or the physician when talking about sexuality because they can't find the terms to talk about this subject often considered taboo and the age or gender difference. This aspect of the disease should be considered by physicians who care for patients with psoriasis, especially dermatologists. Finally, other strategies should be implemented, such as patient talk groups, referral guides or personalised therapeutic education.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis and sexuality: Patients express their feelings

Salle

Halioua

Fur³

et al. 2022

Skin Health and Disease

View full text Add to dashboard Cite

show abstract

“…Static Physician Global Assessment of Genitalia ( sPGA-G): this clinician-reported outcome measure, developed specifically for grading the severity of genital psoriasis, assesses erythema, plaque elevation, and scaling on a 6-point scale (0: clear; 5: very severe) [ 6 ].…”

Section: Methodsmentioning

confidence: 99%

“…Genital involvement occurs in over 60% of psoriasis patients throughout the course of their illness [ 1 – 3 ]. This condition is associated with a major impact to quality of life (QoL), since it causes intense burning and pruritus, and is associated with embarrassment in engaging sexual intercourses significantly impacting their quality of life [ 4 – 6 ]. Nevertheless, genital psoriasis is hardly diagnosed in clinical practice and its treatment poses challenges due to its classification as a ‘difficult-to-treat’ area [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Orsini,

Malagoli,

Balato

et al. 2024

Dermatology Practical &Amp; Conceptual

View full text Add to dashboard Cite

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

show abstract

Updates on Psoriasis in Special Areas

Butacu,

Toma,

Negulet

et al. 2024

JCM

View full text Add to dashboard Cite

Special areas of involvement in psoriasis include the scalp region, the palms and soles, genital areas, as well as intertriginous sites. The involvement of these topographical regions is associated with important physical and emotional implications, resulting in reduced quality of life, social isolation, and work disability. Palms and soles can be affected as part of the generalized form of psoriasis or can be exclusively affected as palmo-plantar psoriasis. Nail involvement may be encountered in 10–55% of patients with psoriasis, while scalp involvement occurs in 45–56% of individuals with psoriasis. Genital involvement may be the only manifestation of cutaneous psoriasis in 2–5% of patients. Inverse or intertriginous psoriasis represents a special variant of psoriasis as it may mimic and be difficult to differentiate from other dermatological entities that involve the intertriginous skin, such as bacterial or fungal infections, eczema, or lichen planus. Treatment of psoriasis in special areas is challenging due to the facts that special areas are more resistant to standard therapies and are more sensitive to potent local treatments. Biological therapies, proven to be more efficient than standard therapies, are not widely available in the absence of extensive skin involvement. This manuscript aims to provide an up-to-date literature review on psoriasis in special areas, benefiting the everyday clinical practice of physicians in optimizing the evaluation and treatment of their patients.

show abstract

Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial

Cited by 3 publications

References 8 publications

Psoriasis and sexuality: Patients express their feelings

Psoriasis and sexuality: Patients express their feelings

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Updates on Psoriasis in Special Areas

Contact Info

Product

Resources

About